Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma - Trial NCT01390571
Access comprehensive clinical trial information for NCT01390571 through Pure Global AI's free database. This Phase 1 trial is sponsored by Cancer Research UK and is currently Completed. The study focuses on Brain and Central Nervous System Tumors. Target enrollment is 34 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Cancer Research UK
Timeline & Enrollment
Phase 1
Jul 01, 2011
Jun 20, 2017
Primary Outcome
Detection of olaparib in tumor tissue using liquid chromatography mass spectrometry (LC-MS) seen in at least 1 out of the 6 patients treated in stage 1 of the study,Maximum-tolerated dose of olaparib in combination with temozolomide (stage 2),Toxicity profile and dose-limiting toxicity as assessed by NCI CTCAE Version 4.02 (stage 2)
Summary
RATIONALE: Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed
 for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to
 stop the growth of tumor cells, either by killing the cells or by stopping them from
 dividing. Olaparib may help temozolomide kill more tumor cells by making tumor cells more
 sensitive to the drug.
 
 PURPOSE: This phase I trial is studying the side effects and best dose of olaparib and
 temozolomide in treating patients with relapsed glioblastoma.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT01390571
Non-Device Trial